Cargando…

Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child

BACKGROUND: In the United States, human papillomavirus (HPV) vaccination rates remain low. The President’s Cancer Panel suggests that effective messaging about the HPV vaccination focus on the vaccine’s safety, efficacy, ability to prevent cancer, and recommendation at ages 11- to 12-years. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Staras, Stephanie A. S., Bylund, Carma L., Mullis, Michaela D., Thompson, Lindsay A., Hall, Jaclyn M., Hansen, Marta D., Fisher, Carla L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779937/
https://www.ncbi.nlm.nih.gov/pubmed/36550434
http://dx.doi.org/10.1186/s12889-022-14852-9
_version_ 1784856732722266112
author Staras, Stephanie A. S.
Bylund, Carma L.
Mullis, Michaela D.
Thompson, Lindsay A.
Hall, Jaclyn M.
Hansen, Marta D.
Fisher, Carla L.
author_facet Staras, Stephanie A. S.
Bylund, Carma L.
Mullis, Michaela D.
Thompson, Lindsay A.
Hall, Jaclyn M.
Hansen, Marta D.
Fisher, Carla L.
author_sort Staras, Stephanie A. S.
collection PubMed
description BACKGROUND: In the United States, human papillomavirus (HPV) vaccination rates remain low. The President’s Cancer Panel suggests that effective messaging about the HPV vaccination focus on the vaccine’s safety, efficacy, ability to prevent cancer, and recommendation at ages 11- to 12-years. We aimed to develop messages about HPV vaccine that include the President Cancer Panel’s suggestions and were acceptable to caregivers of adolescents. METHODS: From August to October 2020, we conducted one-hour, Zoom videoconference focus groups with caregivers who lived in Florida, had an 11- to 12-year-old child, and had not had any of their children receive the HPV vaccine. Focus group moderators asked caregivers to react to three videos of clinician (i.e., MD, DO, APRN, PA) recommendations and three text message reminders. Thematic analysis was conducted using the constant comparative method and led by one author with qualitative analysis expertise. Two additional authors validated findings. RESULTS: Caregivers (n = 25 in six groups) were primarily non-Hispanic white (84%) and educated (64% had at least an Associate’s degree). Approximately a third of caregivers had delayed (44%) or decided against a vaccine for their child (36%). Caregivers described six preferred message approaches: recognize caregivers’ autonomy, balanced benefits and risks, trustworthy sources, increased feasibility of appointment scheduling, information prior to decision point, and preferred personalized information. Caregivers expressed a desire to have the follow-up doses mentioned in the introduction. CONCLUSIONS: HPV vaccine messages, whether delivered by a clinician or via text message, will be more acceptable to caregivers if they approach HPV vaccination as the caregivers’ decision, and include information from trusted sources to help caregivers make an informed choice.
format Online
Article
Text
id pubmed-9779937
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97799372022-12-23 Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child Staras, Stephanie A. S. Bylund, Carma L. Mullis, Michaela D. Thompson, Lindsay A. Hall, Jaclyn M. Hansen, Marta D. Fisher, Carla L. BMC Public Health Research BACKGROUND: In the United States, human papillomavirus (HPV) vaccination rates remain low. The President’s Cancer Panel suggests that effective messaging about the HPV vaccination focus on the vaccine’s safety, efficacy, ability to prevent cancer, and recommendation at ages 11- to 12-years. We aimed to develop messages about HPV vaccine that include the President Cancer Panel’s suggestions and were acceptable to caregivers of adolescents. METHODS: From August to October 2020, we conducted one-hour, Zoom videoconference focus groups with caregivers who lived in Florida, had an 11- to 12-year-old child, and had not had any of their children receive the HPV vaccine. Focus group moderators asked caregivers to react to three videos of clinician (i.e., MD, DO, APRN, PA) recommendations and three text message reminders. Thematic analysis was conducted using the constant comparative method and led by one author with qualitative analysis expertise. Two additional authors validated findings. RESULTS: Caregivers (n = 25 in six groups) were primarily non-Hispanic white (84%) and educated (64% had at least an Associate’s degree). Approximately a third of caregivers had delayed (44%) or decided against a vaccine for their child (36%). Caregivers described six preferred message approaches: recognize caregivers’ autonomy, balanced benefits and risks, trustworthy sources, increased feasibility of appointment scheduling, information prior to decision point, and preferred personalized information. Caregivers expressed a desire to have the follow-up doses mentioned in the introduction. CONCLUSIONS: HPV vaccine messages, whether delivered by a clinician or via text message, will be more acceptable to caregivers if they approach HPV vaccination as the caregivers’ decision, and include information from trusted sources to help caregivers make an informed choice. BioMed Central 2022-12-22 /pmc/articles/PMC9779937/ /pubmed/36550434 http://dx.doi.org/10.1186/s12889-022-14852-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Staras, Stephanie A. S.
Bylund, Carma L.
Mullis, Michaela D.
Thompson, Lindsay A.
Hall, Jaclyn M.
Hansen, Marta D.
Fisher, Carla L.
Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child
title Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child
title_full Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child
title_fullStr Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child
title_full_unstemmed Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child
title_short Messaging preferences among Florida caregivers participating in focus groups who had not yet accepted the HPV vaccine for their 11- to 12-year-old child
title_sort messaging preferences among florida caregivers participating in focus groups who had not yet accepted the hpv vaccine for their 11- to 12-year-old child
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779937/
https://www.ncbi.nlm.nih.gov/pubmed/36550434
http://dx.doi.org/10.1186/s12889-022-14852-9
work_keys_str_mv AT starasstephanieas messagingpreferencesamongfloridacaregiversparticipatinginfocusgroupswhohadnotyetacceptedthehpvvaccinefortheir11to12yearoldchild
AT bylundcarmal messagingpreferencesamongfloridacaregiversparticipatinginfocusgroupswhohadnotyetacceptedthehpvvaccinefortheir11to12yearoldchild
AT mullismichaelad messagingpreferencesamongfloridacaregiversparticipatinginfocusgroupswhohadnotyetacceptedthehpvvaccinefortheir11to12yearoldchild
AT thompsonlindsaya messagingpreferencesamongfloridacaregiversparticipatinginfocusgroupswhohadnotyetacceptedthehpvvaccinefortheir11to12yearoldchild
AT halljaclynm messagingpreferencesamongfloridacaregiversparticipatinginfocusgroupswhohadnotyetacceptedthehpvvaccinefortheir11to12yearoldchild
AT hansenmartad messagingpreferencesamongfloridacaregiversparticipatinginfocusgroupswhohadnotyetacceptedthehpvvaccinefortheir11to12yearoldchild
AT fishercarlal messagingpreferencesamongfloridacaregiversparticipatinginfocusgroupswhohadnotyetacceptedthehpvvaccinefortheir11to12yearoldchild